Interestingly, the most common negative immune checkpoint PD‐L1 was found to be obviously upregulated in tumor tissues of RBC‐Nanovaccines‐treated mice according to immunofluorescence (IF) and immunohistochemistry (IHC) analysis (Appendix Fig S21). This evidence concerns the gene CD274 and neoplasm.